GlassScriptPhysician profile
Clair D Felpel
NPI 1962849679
$3,827.79
in general payments reported to CMS, 2019-2025
30 companies · $961 in 2025
The $961 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.66 · 2020: $29.79 · 2021: $90.26 · 2022: $370 · 2023: $1,304 · 2024: $1,029 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,295.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $558.51 | 2022-2025 | |
| Lilly USA, LLC | $523.75 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $440.61 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $361.97 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $256.87 | 2021-2025 | |
| Glaxosmithkline, LLC. | $221.56 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.43 | 2021-2025 | Xifaxan |
| Amgen INC. | $128.00 | 2022-2025 | Repatha, Repatha, Otezla |
| Abbott Laboratories | $127.22 | 2021-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $115.26 | 2023 | Verquvo, Belsomra, Steglatro |
| Viiv Healthcare Company | $101.62 | 2022-2024 | Cabenuva, Dovato |
| Dexcom, INC. | $94.90 | 2024-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $83.55 | 2023-2025 | Gemtesa |
| Esperion Therapeutics, INC. | $83.46 | 2022-2024 | Nexletol |
| Astellas Pharma US INC | $78.18 | 2023-2025 | Veozah |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $63.96 | 2023-2025 | Livalo, Zoryve, Seglentis |
| Ardelyx, INC. | $60.38 | 2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.88 | 2023-2024 | Jardiance, Ofev |
| Exact Sciences Corporation | $50.57 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $31.02 | 2023 | |
| Alkermes, INC. | $28.78 | 2019-2020 | |
| Gilead Sciences, INC. | $26.93 | 2023 | |
| Inspire Medical Systems, INC. | $22.55 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $21.60 | 2023 | |
| Xeris Pharmaceuticals, INC. | $20.52 | 2023 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $19.32 | 2023 | Quviviq |
| Medtronic, INC. | $18.56 | 2023 | Minimed 780g |
| Ultragenyx Pharmaceutical INC. | $18.01 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.78 | 2022 | |
| Corium, LLC | $12.25 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clair Felpel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.